Article

Vasoactive drugs and acute kidney injury.

Department of Intensive Care and Medicine, Austin Hospital, Melbourne, Australia.
Critical care medicine (Impact Factor: 6.15). 05/2008; 36(4 Suppl):S179-86. DOI: 10.1097/CCM.0b013e318169167f
Source: PubMed

ABSTRACT The use of norepinephrine, and probably vasopressor therapy in general, in intensive care patients with hypotensive vasodilatation despite fluid resuscitation and evidence of acute kidney injury remains the subject of much debate and controversy. Although there is concern about the use of these drugs, these concerns are unfounded. At this time, the experimental and human data strongly suggest that, in these patients, vasopressor therapy is safe and probably beneficial from a renal, and probably general, point of view. On the basis of currently available evidence, in hypotensive vasodilated patients with acute kidney injury, restoration of blood pressure within autoregulatory values should occur promptly with noradrenaline and be sustained until such vasodilatation dissipates. The additional role of other vasopressors in these situations remains unclear. The addition of vasopressin may be helpful in individual patients, but widespread use is not supported by evidence. Alpha-dose dopamine has no advantages over noradrenaline and is not as reliably effective in restoring blood pressure and urine output. Its widespread use cannot be supported in patients with vasodilatation and acute kidney injury. Other vasopressor drugs such as epinephrine and phenylephrine may be similar in efficacy to noradrenaline. However, experience and available data with their use is vastly less than with noradrenaline. Adrenaline, in addition, is associated with hyperglycemia, hyperlactatemia, acidosis, and hypokalemia. Terlipressin appears useful in patients with acute kidney injury secondary to hepatorenal syndrome. Whether it is superior to noradrenaline in this setting remains uncertain, and more studies are needed before recommendations can be made.

0 Followers
 · 
108 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJETIVOS: Lesão renal aguda caracteriza-se pela redução súbita e, em geral, reversível da função renal com perda da capacidade de manutenção da homeostase do organismo. Em pediatria, as principais causas de lesão renal aguda são sepse, uso de drogas nefrotóxicas e isquemia renal nos pacientes criticamente enfermos. Nesses pacientes, a incidência de lesão renal aguda varia de 20 a 30%, resultando em aumento da taxa de morbi-mortalidade de 40 a 90%. Este estudo tem como objetivo avaliar a incidência de lesão renal aguda nos pacientes internados em unidade de terapia intensiva, classificar a gravidade da lesão renal aguda de acordo com o Pediatric Risk, Injury, Failure, Loss, End-Stage (pRIFLE), analisar a relação entre lesão renal aguda e a gravidade através do Pediatric Index of Mortality (PIM) e estudar os fatores prognósticos associados. MÉTODOS: Realizou-se um estudo prospectivo entre julho de 2008 a janeiro de 2009 dos pacientes internados na unidade de terapia intensiva pediátrica do Hospital Infantil Joana de Gusmão – Florianópolis (SC) - Brasil. Todos os pacientes foram analisados diariamente através do débito urinário e creatinina sérica e classificados de acordo com pRIFLE. RESULTADOS: No período de acompanhamento foram internadas 235 crianças. A incidência de lesão renal aguda foi de 30,6%, sendo que o pRIFLE máximo durante a internação foi de 12,1% para R, 12,1% para I e 6,4% para F. A taxa de mortalidade foi de 12,3%. Os pacientes que evoluíram com lesão renal aguda apresentaram risco dez vezes maior de óbito em relação aos não expostos. CONCLUSÃO: Lesão renal aguda é uma entidade comum nos pacientes críticos. O diagnóstico precoce a e instituição imediata de medidas terapêuticas adequadas a cada situação clínica podem alterar o curso e a gravidade do envolvimento renal reduzindo a morbi-mortalidade do paciente.
    Revista Brasileira de Terapia Intensiva 06/2010; 22(2):166-174. DOI:10.1590/S0103-507X2010000200011
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiorenal syndrome (CRS) includes a broad spectrum of diseases within which both the heart and kidneys are involved, acutely or chronically. An effective classification of CRS in 2008 essentially divides CRS in two main groups, cardiorenal and renocardiac CRS, based on primum movens of disease (cardiac or renal); both cardiorenal and renocardiac CRS are then divided into acute and chronic, according to onset of disease. The fifth type of CRS integrates all cardiorenal involvement induced by systemic disease. This article addresses the pathophysiology, diagnosis, treatment, and outcomes of the 5 distinct types of CRS.
    Heart Failure Clinics 04/2014; 10(2):251-280. DOI:10.1016/j.hfc.2013.12.003 · 1.41 Impact Factor